Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Silent who wrote (459)	11/19/2003 10:59:22 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 496

Joseph: I owned the stock because of the large-market potential of the development projects (GPI 1485, cyclophilin ligands in general, and PARP and NAALADase inhibitors). I find the propofol prodrug to be a very hard sell, as propofol is very popular among those who use it (not my research..... rkrw and others have done the footwork and convinced me). If there is some definitive description of side effects associated with the oil emulsion, then I'll jump in FAST. But I am completely dismayed that, after all this time, Craig et al. are throwing in the towel and going for a molecule with -- IMO -- limited potential. I prefer companies that go for broke. I often find companies that succeed in making it, too. ;-) Dunno.......... just doesn't look fun to me anymore. But my type of company is not the type that all of the "how to invest in biotech" gurus look for, so your concern is probably misplaced...... others will like the company more now than before IIb/IIIa. Rick